根据第 8 版美国癌症联合委员会 (AJCC) 病理分类对全球患者队列评估视网膜母细胞瘤 (RB) 的结果。回顾性、多中心、洲际合作研究 参与者：1411 名患者 干预措施：主要摘除术联合/不联合辅助化疗/放疗 主要结果：眼眶肿瘤复发、肿瘤相关转移、肿瘤相关死亡 结果：根据第 8 版 AJCC 病理分类，645 只（46%）眼属于 pT1，其中 164 只（ 11%）属于 pT2，493（35%）属于 pT3，109（8%）属于 pT4 类别。在平均 38 个月（中位 35 个月；<1-149 个月）的随访中，8 名 (1%)、5 名 (3%)、22 名 (4%) 和 25 名 (23%) 患者出现眼眶肿瘤复发) 分别为 pT1、pT2、pT3 和 pT4 (p<0.001) 类别；肿瘤相关转移分别见于 7 个（1%）、5 个（3%）、40 个（8%）和 46 个（43%）pT1、pT2、pT3 和 pT4 类别（p<0.001）；肿瘤相关死亡分别见于 12 例 (2%)、7 例 (4%)、64 例 (13%) 和 64 例 (59%) pT1、pT2、pT3 和 pT4 (p<0.001) 类别。结果的多变量 Cox 比例风险分析显示 pT 类别和辅助治疗是结果的独立预测因素。 pT3b (p=0.005)、pT3c (p<0.001)、pT3d (p<0.001) 和 pT4 (p<0.001) 类别的眼眶复发风险更大； pT2a (p=0.015)、pT3a (p<0.001)、pT3b (p<0.001)、pT3c (p<0.001)、pT3d (p<0.001) 和 pT4 (p<0.001) 与肿瘤相关的风险更大转移;和类别 pT2a (p=0.068)、pT2b (p=0.004)、pT3a (p<0.001)、pT3b (p<0.001)、pT3c (p<0.001)、pT3d (p<0.001) 和 pT4 (p<0.001)与 pT1 类别相比，肿瘤相关死亡的风险更大。未接受辅助治疗的患者在 pT3b (p=0.005)、pT3c (p=0.003) 和 pT4 (p=0.002) 类别中眼眶肿瘤复发的风险更大； pT3a (p=0.001)、pT3b (p=0.01)、pT3c (p=0.001) 和 pT4 (p=0.007) 类别中肿瘤相关转移的风险更大；与接受辅助治疗的患者相比，pT3a (p<0.001)、pT3b (p=0.009)、pT3c (p=0.018) 和 pT4 (p<0.001) 类别中的肿瘤相关死亡。第 8 版 AJCC 病理分类预测接受 RB 初次摘除术的患者的结果，辅助治疗与 pT3 和 pT4 类别中较低的眼眶复发、肿瘤相关转移和肿瘤相关死亡的风险相关。版权所有 © 2024。由 Elsevier Inc. 出版。

To evaluate the outcomes of retinoblastoma (RB) based on the 8th edition of the American Joint Committee on Cancer (AJCC) pathological classification in a global cohort of patients.Retrospective, multicentre, intercontinental collaborative study PARTICIPANTS: 1411 patients INTERVENTION(S): Primary enucleation with/without adjuvant chemotherapy/radiotherapy MAIN OUTCOMES(S): Orbital tumor recurrence, tumor-related metastasis, tumor-related death RESULTS: Based on the 8th edition AJCC pathological classification, 645 (46%) eyes belonged to pT1, 164 (11%) to pT2, 493 (35%) to pT3, and 109 (8%) to pT4 categories. At a mean follow-up of 38 months (median, 35 months; <1-149 months), orbital tumor recurrence was seen in 8 (1%), 5 (3%), 22 (4%) and 25 (23%) of pT1, pT2, pT3, and pT4 (p<0.001) categories, respectively; tumor-related metastasis was seen in 7 (1%), 5 (3%), 40 (8%), and 46 (43%) of pT1, pT2, pT3, and pT4 (p<0.001) categories, respectively; tumor-related death was seen in 12 (2%), 7 (4%), 64 (13%), and 64 (59%) of pT1, pT2, pT3, and pT4 (p<0.001) categories, respectively. Multivariate Cox proportional hazards analysis of outcomes revealed pT category and adjuvant therapy as independent predictors of outcomes. Categories pT3b (p=0.005), pT3c (p<0.001), pT3d (p<0.001), and pT4 (p<0.001) had a greater hazard for orbital recurrence; categories pT2a (p=0.015), pT3a (p<0.001), pT3b (p<0.001), pT3c (p<0.001), pT3d (p<0.001) and pT4 (p<0.001) had a greater hazard for tumor-related metastasis; and categories pT2a (p=0.068), pT2b (p=0.004), pT3a (p<0.001), pT3b (p<0.001), pT3c (p<0.001), pT3d (p<0.001) and pT4 (p<0.001) had a greater hazard for tumor-related death when compared to the pT1 category. Patients who did not receive adjuvant therapy had greater hazards of orbital tumor recurrence in categories pT3b (p=0.005), pT3c (p=0.003), and pT4 (p=0.002); greater hazards of tumor-related metastasis in categories pT3a (p=0.001), pT3b (p=0.01), pT3c (p=0.001), and pT4 (p=0.007); and tumor-related death in categories pT3a (p<0.001), pT3b (p=0.009), pT3c (p=0.018), and pT4 (p<0.001) when compared to those who received adjuvant therapy.The 8th edition AJCC pathological classification predicts outcomes in patients undergoing primary enucleation for RB, and adjuvant therapy is associated with a lower risk of orbital recurrence, tumor-related metastasis, and tumor-related death in the pT3 and pT4 categories.Copyright © 2024. Published by Elsevier Inc.